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David McKenzie2, Marcela Bilek2, Anthony S Weiss2
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Background: Metallic endovascular stents have suboptimal biocompatibility reducing
their clinical efficacy. We sought to develop a unique non-thrombogenic metal/protein
interface to covalently bind proteins in their bioactive state to metallic surfaces, to
achieve vascular biointegration of stents. We then bound recombinant human
tropoelastin (TE), a major regulator of vascular cells in vivo, and investigated the
biocompatibility of TE-coated metal compared to 316L stainless steel (SS).
Methods: A pulsed plasma deposition system was developed to deposit a plasma-
activated coating (PAC), a carbon-based surface capable of covalent protein binding,
on 316L stainless steel sheets or on slotted tube stents. Horseradish peroxidase and
human recombinant TE were bound to PAC. PAC surfaces were characterized for 1)
coating durability, 2) immobilized protein adhesion, activity and stability, 3) cellular
interactions and 4) thrombogenicity.
Results: PAC is extremely smooth (1-2nm rms roughness), is wear resistant using a 3
week pulsed flow of 500ml/min, 100pulses/min, and resists delamination after stent
expansion. Horseradish peroxidase activity (a probe for retention of protein
conformation) remained higher after 10 days when bound to PAC vs SS. TE remained
attached to PAC despite SDS washing, and incubation with supraphysiological serum
enzymes, indicating covalent binding. PAC+TE coating dramatically enhanced
endothelial cell attachment and proliferation by 86.3±10.5% (p<0.01) & 76.9±6.4%
(p<0.001 vs Control) respectively. Moreover, thrombus weight was reduced on PAC
& PAC+TE by 94.0±0.9% and 93±1.2% respectively (p<0.001 vs Control) in a
modified Chandler loop, and time to clot formation was reduced 3-fold. Serum soluble
P-selectin was reduced by 25.3±8.7% and 24.5±8.7% on PAC and PAC+TE
respectively, p<0.05.
Conclusion: PAC is durable, non-thrombogenic metal coating that enables covalent
binding of bioactive proteins to stents. PAC+TE enhanced endothelialisation and
remained non-thrombogenic. This has profound potential to improve stent efficacy.
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Comparison of bivalirudin versus heparin during PCI in patients receiving
prasugrel M Hamon, S Marso, SV Rao, M Valgimigli, F Verheugt, A Gershlick,
Y Wang, GP Steg, E Deliargyris
Martial Hamon
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Background: Antiplatelet agents are used as adjunctive agents with BIV or
unfractionated or low molecular weight heparin (HEP) ± glycoprotein IIb/IIIa inhibitor
(GPI) in PCI. Prasugrel (PRAS) is a recently introduced agent and thus little data is
available regarding the use of PRAS with BIV.
Methods: Using the Premier Perspective database, 6986 patients who underwent
elective, urgent, or primary PCI between Q3 2009 and Q4 2010 from 166 US hospitals
were identified. Patients were treated with either BIV (n=3377) or HEP±GPI (n=3609)
on the day of PCI and given PRAS before or on the day of PCI. Outcomes of interest
included bleeding, transfusion, death, and hospital length of stay. To control for patient
and hospital level characteristics, propensity score matching analyses were performed.
Results: Outcomes are shown in the table.
Conclusion: In this analysis of real world data, patients receiving BIV and PRAS had
less bleeding than with HEP ± GPI and required less transfusion.
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Combination Abciximab and t-PA Use with the Trellis™-6 Peripheral Infusion
System for Thrombotic Occlusion of the Superficial Femoral and Popliteal
Arteries
Eric J Dippel, Penny Stoakes, Desyree Weakley
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Background: The Trellis™-6 (T6) catheter (Coviden, Mansfield, MA, USA) has
proximal and distal occlusion balloons with drug infusion holes inbetween and
mechanical drug dispersion capabilities allowing mechanical pharmacological
thrombolysis of the superficial femoral (SFA) and popliteal (Pop) arteries. Yet, the
optimal dose of lytics and ideal dwell time of the T6 catheter are unknown. We report
our experience with the combination abciximab (abc), t-PA and T6 in the SFA/Pop.
Methods: A retrospective review of our database of pts with thrombotic stent occlusion
(TSO) of the SFA/Pop and consecutively treated with the T6 catheter. The following
demographic variables were recorded: Age, Gender, Lesion length, Anti-thrombotic
tx, Anti-platelet tx, Thrombolytic tx, T6 dwell time, Adjunctive thrombo-embolic tx,
Pre/Post Hemoglobin (Hg), Bleeding complications, Length of stay (LOS).
Results: 15 patients met the above criteria. All patients received: clopidogrel 600mg
and aspirin 325mg pre-procedure; bivalirudin 0.75mg/kg IV bolus & 1.75mg/kg/hr
infusion IV for procedure duration; abc 0.25mg/kg bolus IA via T6, divided if multiple
dwells, & 10mcg/min IV x 12 hours; t-PA 10mg/30cm of T6 catheter with 10min dwell,
53% required 2 dwells for lesions >30cm. Age 72.4±9.3, Male 53%, Lesion length
37±11cm. The majority of the thrombus was lysed in all cases; adjunctive thrombo-
embolic tx was used in 53% of the cases to clean up minor residual thrombus. Pre Hg
13.0±1.9g/dL, Post Hg 10.9±2.2g/dL. A closure device was used in all cases. Bleeding
complications: 1 pt had a GI bleed, 3 pts had >4cm groin hematoma, 5 pts had
significant groin oozing, 3 pts had Hg drop > 3g/dL and received PRBC transfusion,
there were no intra-cranial bleeds. The average LOS was 1.7±1.3dys.
Conclusion: Combination of abc & t-PA delivered via the T6 catheter was efficacious
in minutes (compared to an overnight lytic infusion) for TSO of the SFA/Pop and
demonstrated moderate minor bleeding and occasional major bleeding. Comparative
studies of pharmacologic agents and dwell times are warranted.
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Background: According to recent studies Bivalirudin, in comparison to heparin,
provides reduced clinical event rates after percutaneous coronary interventions. In
peripheral interventions it is even more important to obtain a predictable and reliable
anticoagulation level because of the higher risk of the vascular and bleeding
complications. Therefore, and in the light of increasing demands for health care cost
reduction, we believe that by combining Bivalirudin with Vascular Closure Device
(VCD), we can safely discharge patients within 5 hours after the procedure. The aim
of this study was to evaluate the incidence of early and late complication rates after
the same-day discharge peripheral intervention with the use of Bivalirudin as the
procedural anticoagulant.
Methods: Between January 2008 and May 2011, in San Antonio Endovascular & Heart
Institute 409 peripheral interventions were performed in 188 consecutive patients.
Patients received Bivalirudin in accordance with the standard protocol. Hemostasis
was obtained with Mynx VCD. Primary end point (Major Vascular Complications):
retroperoneal bleeding, urgent hospitalization, hematoma>5cm and pseudoaneurysm.
Secondary end point (Minor Vascular Complications): ecchymosis, hematoma <5cm
and adjunctive manual compression. Follow up was performed three times: before
discharge, next day and 30 (±5) days after the procedure.
Results: 168 procedures (41.1%) were performed with antegrade approach. Hemostasis
was achieved after 409 (100%) procedures. Mean times to hemostatsis and ambulation
were 2.5+/-3.9 min and 3.1+/-2.8 hours, respectively. All patients were discharged on
the day of intervention. Primary end points noted in 16 cases (3.9%) included 7
hematomas>5cm, 3 retroperoneal bleedings, 2 pseudoaneurysms and 4 hospitalizations.
Secondary end point was observed after 61 (14.9%) procedures (19 hematomas<5cm,
4 adjunctive manual compressions, 38 ecchymosis<20cm).
Conclusion: Bivalirudin, thanks to favorable pharmacokinetics and
pharmacodynamics, is an attractive alternative to heparin in Peripheral Interventions
and seems to ensure safe discharge 5 hours after the procedure.
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Background: Some patients (pts) are unable to tolerate apirin due to sensitivity,
precluding them from the benefits of this therapy. The aim of this study was to test the
safety and efficacy of a new standard desensitization procedure, using escalating low
doses of aspirin in pts with acetylsalicylic acid sensitivity.
Methods: Out of 3080 pts undergoing coronary angiography, seventy-seven had a
history of aspirin sensitivity (2.5%). They were admitted for acute coronary syndrome
(67.2%) or stable angina (32.8%). A history of cutaneous reactions was reported in
76% of pts, respiratory sensitivity in 21.5%, whereas 2.5% had a history of anaphylactic
shock. All pts underwent the desensitization procedure: six sequential doses of aspirin
(1, 5, 10, 20, 40, and 100 mg) administered orally at predefined intervals, with the
procedure lasting 5.5 hours. None received pretreatment with antihistamines or
corticosteroids, and beta-blockers were withheld 24 hours before desensitization. Blood
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